Xtl Biopharmaceuticals (XTLB) Net Income towards Common Stockholders (2009 - 2024)
Xtl Biopharmaceuticals (XTLB) posted quarterly Net Income towards Common Stockholders of -$6.2 million for Q4 2024, down 366.92% year-on-year from $2.3 million in Q1 2024, and down 403.07% on a QoQ basis from $2.0 million in Q3 2024.
Xtl Biopharmaceuticals (XTLB) Net Income towards Common Stockholders (2009 - 2024) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Net Income towards Common Stockholders for 16 consecutive years, with -$6.2 million the latest figure, recorded in Q4 2024.
- Quarterly Net Income towards Common Stockholders fell 366.92% year-over-year to -$6.2 million in Q4 2024, while the trailing twelve-month figure through Dec 2025 was -$4.2 million (up 5.0% YoY) and the FY2025 annual result came in at -$6.2 million, changed 0.0% from the prior year.
- Net Income towards Common Stockholders retreated to -$6.2 million in Q4 2024 per XTLB's latest filing, from $2.0 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for XTLB reached as high as $2.0 million in Q3 2024 and fell as low as -$6.2 million in Q4 2024.
- A 5-year average of -$400474.1 and a median of -$221001.0 in 2022 frame the typical range for Net Income towards Common Stockholders.
- The largest YoY upside for Net Income towards Common Stockholders was 114999900.0% in 2021 against a maximum downside of 17299840.0% in 2021.
- Year by year, Net Income towards Common Stockholders stood at -$2.0 in 2020, then tumbled by 11250050.0% to -$225003.0 in 2021, then tumbled by 582.21% to -$1.5 million in 2022, then gained by 13.36% to -$1.3 million in 2023, then tumbled by 366.92% to -$6.2 million in 2024.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$6.2 million, $2.0 million, and -$704000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | -0.68 |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -6.21 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | -704,000.00 |
| Mar 31, 2024 | 485,000.00 |
| Dec 31, 2023 | -1.33 Mn |
| Sep 30, 2023 | 1.01 Mn |
| Jun 30, 2023 | -364,000.00 |
| Mar 31, 2023 | -919,000.00 |
| Dec 31, 2022 | -1.54 Mn |
| Sep 30, 2022 | -221,001.00 |
| Jun 30, 2022 | -285,000.00 |
| Mar 31, 2022 | 72,000.00 |
| Dec 31, 2021 | -225,003.00 |
| Sep 30, 2021 | -864,997.00 |
| Jun 30, 2021 | 1.15 Mn |
| Mar 31, 2021 | 286,000.00 |
| Dec 31, 2020 | -2.00 |
| Sep 30, 2020 | -5.00 |
| Jun 30, 2020 | 1.00 |
| Dec 31, 2019 | -1.44 Mn |